Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry

BACKGROUND: Until the approval of dabigatran etexilate, treatment choices for stroke prevention in patients with atrial fibrillation (AF) were vitamin K antagonists (VKAs) or antiplatelet drugs. This analysis explored whether availability of non‐vitamin K antagonist oral anticoagulants post‐dabigatr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Arrhythm
Egile Nagusiak: Ma, Changsheng, Riou França, Lionel, Lu, Shihai, Diener, Hans‐Christoph, Dubner, Sergio J., Halperin, Jonathan L., Li, Qiang, Paquette, Miney, Teutsch, Christine, Huisman, Menno V., Lip, Gregory Y. H., Rothman, Kenneth J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7279964/
https://ncbi.nlm.nih.gov/pubmed/32528565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/joa3.12321
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak